[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this research study is to test if an imaging drug, not approved by the Food and Drug Administration (FDA), called FES, is useful for evaluating your type of cancer and predicting how well your cancer responds to therapy.
Description
This phase II trial studies F-18 16 alpha-fluoroestradiol (FES) positron emission tomography (PET)/computed tomography (CT) in predicting response to endocrine therapy in patients with newly diagnosed breast cancer that has spread to other parts of the body (metastatic).
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
breast cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
24 Apr 2024.
Study ID: 1705571295 (EAI142)
